AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Thrombopoietin (TPO) regulates megakaryopoiesis and the generation of platelets. Recombinant TPO has been investigated in clinical studies for use in thrombocytopenia with limited success. A new peptibody, AMG 531, has been shown to increase platelet counts in preclinical and Phase 1 and Phase 2 studies and to be generally safe and tolerable in those studies.